🔗 Share this article

While the United States continues making sweeping revisions to its vaccine guidelines, one figure appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus shots throughout the pandemic and has focused upon possible deaths following COVID-19 immunization in her recent tenure at the FDA.

Proposed Changes to Pediatric Immunization Program

Health officials were set to reveal sweeping revisions to the childhood vaccination calendar in December, bringing the US with the Danish vaccine program, it is understood – a major change that would put the US out of step with much of the world with no evidence for benefit. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Høeg is listed to present at the event. She was newly appointed interim head of the FDA’s CDER, the fifth person to lead the division this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting certain childhood shot schedules in the US to become more similar to Denmark, a nation with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Background

Høeg has little discernible experience in medication creation, regulation or management, which has been standard for former directors of the biologics center. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a major agency. She has no expertise in drug approvals.”

Former directors of CBER would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the kind of background that prior appointees who headed CBER have had.”

The drug center has an immense workload at the agency, the former commissioner stated.

“The public just focuses on the novel medication approvals, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and each of these need to be supervised,” she explained. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

There is also, a significant management component to the role, which manages in excess of 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” Woodcock said.

Official Statement and Contentious Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this selection indicates more teamwork among FDA leaders on vaccines, a spokesperson said that the “concerns are based on incorrect premises”.

“This background aligns with the duties of her position,” the spokesperson stated, pointing to the time Høeg spent advising the agency head on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a controversial expedited drug-approval program that reportedly worried her predecessors. “How are these therapies being picked for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed oversight of all drugs, except for shots.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, track record, Howard have noted. She released a study using unverified volunteer-provided data to assess the rate of myocarditis after Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are pose a greater threat than they are.

Part of her “wish list” for the new federal leadership featured revising regulations for novel immunizations and ending “unnecessary” vaccines, she said after the election on a podcast. At the agency, Dr. Høeg has reportedly suggested preventing adolescent males from receiving COVID-19 vaccines.

“She’s an thorough ideologue who starts off with her preconceived notions and works backwards to accommodate the data in a very deceptive, dishonest way,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg aligned with other dissenters, {like|